Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Matsumura Y, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Nishimura N, et al. Among authors: numakura k. Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13. Int J Urol. 2022. PMID: 34902876
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
Konishi S, Hatakeyama S, Numakura K, Narita S, Inoue T, Saito M, Tokui N, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Narita S, Kawaguchi T, Habuchi T, Ohyama C. Konishi S, et al. Among authors: numakura k. Clin Genitourin Cancer. 2019 Oct;17(5):e1080-e1089. doi: 10.1016/j.clgc.2019.07.006. Epub 2019 Jul 20. Clin Genitourin Cancer. 2019. PMID: 31416753
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Numakura K, Kido K, Noro D, Oikawa M, Hosogoe S, Tokui N, Yamamoto H, Narita S, Ito H, Yoneyama T, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Tanaka T, et al. Among authors: numakura k. Int J Urol. 2020 Dec;27(12):1095-1100. doi: 10.1111/iju.14363. Epub 2020 Sep 6. Int J Urol. 2020. PMID: 32893401
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K, Hatakeyama S, Numakura K, Tanaka T, Oikawa M, Noro D, Hosogoe S, Narita S, Inoue T, Yoneyama T, Ito H, Nishimura S, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Kido K, et al. Among authors: numakura k. Int J Clin Oncol. 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16. Int J Clin Oncol. 2021. PMID: 33067647
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Tsushima E, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. Hatakeyama S, et al. Among authors: numakura k. Int J Urol. 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12. Int J Urol. 2021. PMID: 33314387
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group. Miyake M, et al. Among authors: numakura k. BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7. BMC Cancer. 2021. PMID: 33706705 Free PMC article.
166 results